Annual report pursuant to Section 13 and 15(d)

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)

v3.20.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Available-for-sale Securities, Total $ 87,800 $ 38,200  
Amortization of Intangible Assets, Total 61,095 58,715  
Other Assets, Noncurrent, Total 13,522 5,668  
Developed Technology Rights [Member] | Cost of Sales [Member]      
Amortization of Intangible Assets, Total 34,500 33,300 $ 25,300
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]      
Amortization of Intangible Assets, Total 26,600 25,400 $ 21,600
Other Noncurrent Assets [Member]      
Inventory, Finished Goods, Net of Reserves, Non-current 4,646 3,239  
ChemoCentryx, Inc (CCXI) [Member]      
Available-for-sale Equity Securities, Amortized Cost Basis, Total $ 6,600 $ 18,800  
ChemoCentryx, Inc (CCXI) [Member]      
Share Price (in dollars per share) $ 9.30 $ 57.54